AKT1 and Stroke: Thus, SCOP/PHLPP1 KOs may also have improved histological outcomes after a TBI; however, the evolution of secondary cell death pathways after a TBI vs. stroke differs, which could influence the therapeutic efficacy of AKT activation in the setting of trauma11.